TTR and amyloidosis: By cross-referencing medication orders and reconciliations, we confirmed that no additional individuals with P/LP TTR variants were prescribed ATTR therapy—specifically tafamidis, patisiran, inotersen, or diflunisal—to raise suspicion of diagnosed amyloidosis.